Since taking over as finance chief of the small biotech company Aristea Therapeutics Inc. last year, first-time CFO Justin Thacker has stretched into his new strategic responsibilities to help prepare the company for a range of scenarios, including a public offering. Thacker started out as a senior accountant and auditor at PricewaterhouseCoopers, and over the […]

Dr. Woody, chief executive officer of 180 Life Sciences, discusses in this interview the current research surrounding synthetic cannabinoids as a treatment for chronic pain, as well as the development of a new type of medication that would have the potential to offer the benefits of cannabis without any undesirable effects. Imagine waking up with […]

OQ011, a topical ointment for hand-foot skin reaction-related pain, yielded positive safety and efficacy in part 1 of 2 phase 2 NOVA-II trial. Investigators reported that treatment with OQ011 yielded positive patient-reported outcomes in hand-foot skin reaction (HFSR)–related pain associated with VEGFR inhibitor-based therapies, according to findings from part 1 of the phase 2 NOVA-II […]